Dr. Melinda L Telli, MD is a Hematology / Oncology Specialist - Oncologist (Cancer), Internist - General practicing in Palo Alto, CA
She has not yet shared a personalized biography with Doctor.com.… Read more ›
| Institution | Focus | Year |
|---|---|---|
| Internship - Stanford University | Not Specified | |
| Residency - Stanford University, Internal Medicine | 2005 | |
| Residency - Stanford University Medical Center | 2005 | |
| Fellowship - Stanford University Medical Oncology | 2008 | |
| Fellowship - Stanford University School of Medicine CA | 2008 | |
| Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 2008 |
| Certification | Cert. Body | Year |
|---|---|---|
Sub-Specialty: Medical Oncology | Internal Medicine | 2008 |
| Internal medicine | Internal Medicine | 2005 |
| Internal medicine Sub-Specialty: Medical Oncology | Internal Medicine | Not Specified |
| Internal medicine Sub-Specialty: Medical Oncology | Internal Medicine | 2008 |
| Position | Organization | Time |
|---|---|---|
| Member | Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy | Present |
| Member | American Society of Clinical Oncology | 2010 - 2013 |
| Member | Program Committee, ASCO Breast Cancer Symposium | 2010 - 2013 |
| Assistant Professor of Medicine (Oncology) | the Stanford University Medical Center | Present |
| Distinction | Institution | Year |
|---|---|---|
| Susan G. Komen for the Cure | Career Catalyst Research Award | 2012 |
| Stanford University School of Medicine | Oncology Division Teaching Award | 2010, 2010 |
| American Society of Clinical Oncology | Young Investigator Award | 2009 |
| Susan G. Komen for the Cure | Fellowship Award | 2008 |
| American Society of Clinical Oncology | Merit Award | 2008 |
| Stanford Cancer Institute | New Investigator Award | 2011 |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? | 2012 |
| Other Publication | JOURL OF THE AMERICAN COLLEGE OF CARDIOLOGY | Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians | 2010 |
| Other Publication | ANLS OF ONCOLOGY | Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate | 2008 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility | 2007 |
| Other Publication | Jourl of the American Medical Informatics Association | Dymic contrast-enhanced MRI | 2013 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early | 2012 |
| Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
| Other Publication | ture and science of sleep | Prevalence, putative mechanisms | 2012 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Trastuzumab-Related Cardiac Dysfunction | 2011 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California | 2010 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Phyllodes tumors of the breast: tural history, diagnosis, and treatment. | 2007 |
| Other Publication | BIOCHEMICAL PHARMACOLOGY | Epidermal growth factor | 1999 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer | 2013 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? | 2012 |
| Other Publication | LANCET ONCOLOGY | PARP inhibitors in cancer: moving beyond BRCA | 2011 |
| Other Publication | BREAST CANCER RESEARCH AND TREATMENT | Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry | 2011 |
| Other Publication | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians | 2010 |
| Other Publication | ANNALS OF ONCOLOGY | Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate | 2008 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility | 2007 |
| Other Publication | Breast cancer research : BCR | Patient-derived xenografts of triple | 2014 |
| Other Publication | Radiology | (18)F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. | 2014 |
| Other Publication | American Society of Clinical Oncology educational book / ASCO. America | Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. | 2014 |
| Other Publication | BMC cancer | Single cell mutational analysis of PIK3CA in circulating tumor cells | 2014 |
| Other Publication | Journal of the American Medical Informatics Association | Dynamic contrast-enhanced MRI | 2013 |
| Other Publication | BREAST CANCER RESEARCH AND TREATMENT | A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk | 2013 |
| Other Publication | AMIA Summits on Translational Science proceedings AMIA Summit on Trans | Qualitative and quantitative image-based biomarkers of therapeutic response in triple | 2013 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early | 2012 |
| Other Publication | BREAST CANCER RESEARCH AND TREATMENT | Breast cancer phenotype in women with TP53 germline mutations | 2012 |
| Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
| Other Publication | Nature and science of sleep | Prevalence, putative mechanisms | 2012 |
| Other Publication | HEART FAILURE CLINICS | Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? | 2011 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Trastuzumab-Related Cardiac Dysfunction | 2011 |
| Other Publication | Clinical advances in hematology & oncology : H&O | PARP inhibitors in breast cancer. | 2010 |
| Other Publication | CLINICAL BREAST CANCER | Novel Treatment Approaches for Triple-Negative Breast Cancer | 2010 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California | 2010 |
| Other Publication | CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | Longer Relative Telomere Length in Blood from Women with Sporadic | 2010 |
| Other Publication | CLINICAL BREAST CANCER | First-Line Chemotherapy for Metastatic Breast Cancer | 2009 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Phyllodes tumors of the breast: natural history, diagnosis, and treatment. | 2007 |
| Other Publication | BIOCHEMICAL PHARMACOLOGY | Epidermal growth factor | 1999 |
Dr. Melinda L Telli, MD has not yet indicated the hospitals that she is affiliated with.
Accepts New Patients: Yes
Dr. Melinda L Telli, MD has not yet listed the medications that she commonly prescribes.
Dr. Melinda L Telli, MD has not yet added any information about her practice's billing policies and payment options.
